Aprepitant is a novel selective neurokinin-1 (NK-1) receptor antagonist. In vitro studies using human liver microsomes show that it is metabolized primarily by CYP3A4 with minor metabolism by CYP2C19 and CYP1A2.
1. Hale, J J., et al., 1998. Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist. Journal of medicinal chemistry. 41(23): 4607-14. PMID: 9804700
2. Campos, D., et al., 2001. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 19(6): 1759-67. PMID: 11251007
3. Van Belle, Simon., et al., 2002. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer. 94(11): 3032-41. PMID: 12115394
4. Majumdar, Anup K., et al., 2006. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. Journal of clinical pharmacology. 46(3): 291-300. PMID: 16490805
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.